A familial cancer service program incorporating multidisciplinary clinic/RRM/RRSO/breast screening for unaffected BRCA1/2 PV carriers was also found to be cost-effective compared to no intervention in one study using real world clinical data, with an ICUR of $23,353/QALY for BRCA1 and $34,831/QALY for BRCA2 [48]. This evidence concerns the gene BRCA2 and cancer.